PAREXEL
Parexel team-up targets clinical trials in China
Biopharmaceuticals company Parexel is teaming up with a patient recruitment company to help accelerate clinical trial recruitment and patient engagement in China. Read more
The tech making it easier to transport medicines
Sanjay Vyas, corporate vice president & Global SBU head of Clinical Trial Supplies & Logistics, PAREXEL International discusses the challenges in transporting certain medicines and how advancements in technology are making things easier. Read more
Parexel and Microsoft team up to improve drug development with wearable tech
A collaboration between biopharmaceuticals company Parexel and Microsoft is using mobile and wearable technology to help improve data access within drug development. Read more
Innovations in drug development positively impact clinical trials and market launches
New innovations in drug development have a positive impact on clinical trial timelines, likelihood of market launch and inclusion on payer formularies, according to a new report released by the Economist Intelligence Unit and commissioned by PAREXEL Read more
Collaborative pilot study set to validate the use of wearables in clinical trials
Global biopharmaceutical services organisation, Parexel, and global life sciences company, Sanofi, are collaborating on a pilot study to advance the use of wearable devices in the collection of data and management of clinical trials. Read more
Patient sensor solution for clinical trial data launched
Parexel International, a global biopharmaceutical services provider, has launched its patient sensor solution. Read more
Our most read stories of 2015
As 2015 is beginning to wrap up European Pharmaceutical Manufacturer has looked at our most popular stories Read more
Parexel launches new clinical trial management system
Parexel has introduced its Impact Express clinical trial management system (CTMS) for small to mid-sized biopharmaceutical companies Read more
Making feasibility more reliable in clinical trials
Muriel Berthier and Denis McMillan, PAREXEL, discuss the key factors for achieving more reliable feasibility in clinical trials Read more
PAREXEL expands model-based drug development services
Additional services and capabilities in model-based drug development (MBDD) are available from PAREXEL's Quantitative Clinical Development (QCD) group. Read more
PAREXEL data-driven monitoring solution delivers increased clinical trial efficacy
Biopharma services provider PAREXEL International has expanded its Perceptive MyTrials data-driven monitoring solution with next generation risk-based monitoring capabilities. Read more
Patient randomisation and trial supply management service simplified
PAREXEL International has announced enhancements to its ClinPhone RTSM (randomisation and trial supply management) service. Read more
Parexel to offer faster enrolment for clinical trial patients
Expansions to its site alliance network mean biopharma specialist will be able to offer clients faster enrolment times for clinical trials. Read more
Parexel acquires British RTSM group
Clinical research organisation Parexel International has acquired ClinIntel, a UK-based group specialised in clinical Randomisation and Trial Supply Management (RTSM). Read more
Time trials
Clock this: Cutting clinical trial start-up time through innovative randomisation and trial supply management services, By Xavier Flinois, president, Parexel Informatics Read more
Parexel International acquires Atlas Medical Services
The acquisition strengthens Parexel’s presence in Turkey, the Middle East and North Africa. Read more
Parexel launches clinical trials solution
Time trials: Parexel International has launched of a new version of its ClinPhone RTSM designed to help clients start clinical trials more quickly. Read more
CRO Reports Successful Start to Year
PAREXEL has had a positive year so far with several key announcements. In April, the company’s technology subsidiary, Perceptive Informatics, a leading eClinical solutions provider, released an enhanced version of its comprehensive IMPACT... Read more
